JP7526174B2 - キナゾリニル-インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用 - Google Patents
キナゾリニル-インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用 Download PDFInfo
- Publication number
- JP7526174B2 JP7526174B2 JP2021523159A JP2021523159A JP7526174B2 JP 7526174 B2 JP7526174 B2 JP 7526174B2 JP 2021523159 A JP2021523159 A JP 2021523159A JP 2021523159 A JP2021523159 A JP 2021523159A JP 7526174 B2 JP7526174 B2 JP 7526174B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- indazol
- stirred
- mixture
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751733P | 2018-10-29 | 2018-10-29 | |
| US62/751,733 | 2018-10-29 | ||
| PCT/IB2019/059238 WO2020089778A1 (en) | 2018-10-29 | 2019-10-28 | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505989A JP2022505989A (ja) | 2022-01-14 |
| JP2022505989A5 JP2022505989A5 (cg-RX-API-DMAC7.html) | 2022-11-04 |
| JP7526174B2 true JP7526174B2 (ja) | 2024-07-31 |
Family
ID=68425185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523159A Active JP7526174B2 (ja) | 2018-10-29 | 2019-10-28 | キナゾリニル-インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210403465A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873607B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7526174B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2969030T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020089778A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53973A (fr) | 2018-10-24 | 2022-02-09 | Viiv Healthcare Uk No 5 Ltd | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
| JP2022506399A (ja) * | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US12564595B2 (en) | 2019-11-28 | 2026-03-03 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent |
| WO2021176366A1 (en) * | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US12703699B2 (en) | 2020-03-06 | 2026-08-11 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN111548349A (zh) * | 2020-05-13 | 2020-08-18 | 厦门云凡医药科技有限公司 | 一种ret激酶抑制剂中间体及其制备方法 |
| TW202448483A (zh) * | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於hiv之治療性化合物 |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| WO2025169059A1 (en) | 2024-02-05 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018035359A1 (en) | 2016-08-19 | 2018-02-22 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| JP2020518601A (ja) | 2017-05-02 | 2020-06-25 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022500425A (ja) | 2018-09-14 | 2022-01-04 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022501370A (ja) | 2018-09-20 | 2022-01-06 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022505637A (ja) | 2018-10-24 | 2022-01-14 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022505597A (ja) | 2018-10-25 | 2022-01-14 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022506399A (ja) | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022509919A (ja) | 2018-11-05 | 2022-01-25 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP7307747B2 (ja) | 2018-04-11 | 2023-07-12 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての4-オキソ-3,4-ジヒドロキナゾリン化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2840095A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| EP2943493B1 (en) | 2013-01-09 | 2017-08-02 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| US9873680B2 (en) | 2014-08-29 | 2018-01-23 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| KR102847339B1 (ko) | 2018-02-16 | 2025-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체 |
-
2019
- 2019-10-28 ES ES19797382T patent/ES2969030T3/es active Active
- 2019-10-28 JP JP2021523159A patent/JP7526174B2/ja active Active
- 2019-10-28 WO PCT/IB2019/059238 patent/WO2020089778A1/en not_active Ceased
- 2019-10-28 US US17/285,680 patent/US20210403465A1/en not_active Abandoned
- 2019-10-28 EP EP19797382.9A patent/EP3873607B1/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018035359A1 (en) | 2016-08-19 | 2018-02-22 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| JP2020518601A (ja) | 2017-05-02 | 2020-06-25 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP7301000B2 (ja) | 2017-05-02 | 2023-06-30 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP7307747B2 (ja) | 2018-04-11 | 2023-07-12 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての4-オキソ-3,4-ジヒドロキナゾリン化合物 |
| JP2022500425A (ja) | 2018-09-14 | 2022-01-04 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022501370A (ja) | 2018-09-20 | 2022-01-06 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022505637A (ja) | 2018-10-24 | 2022-01-14 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022505597A (ja) | 2018-10-25 | 2022-01-14 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022506399A (ja) | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022509919A (ja) | 2018-11-05 | 2022-01-25 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873607A1 (en) | 2021-09-08 |
| WO2020089778A1 (en) | 2020-05-07 |
| EP3873607C0 (en) | 2023-11-29 |
| EP3873607B1 (en) | 2023-11-29 |
| ES2969030T3 (es) | 2024-05-16 |
| JP2022505989A (ja) | 2022-01-14 |
| US20210403465A1 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7500555B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7398448B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| ES2969030T3 (es) | Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana | |
| JP7532354B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7433303B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| US20240374598A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| JP7361766B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP2022509919A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7545414B2 (ja) | ヒト免疫不全ウイルス複製阻害剤 | |
| CN115397424A (zh) | 人类免疫缺陷病毒复制的抑制剂 | |
| WO2021064570A1 (en) | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication | |
| US20230013823A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| EP4041729A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| RU2812128C2 (ru) | Ингибиторы репликации вируса иммунодефицита человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221026 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221026 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231031 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240426 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240709 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240719 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7526174 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |